Addressing Community Oncologists’ Questions About Novel Therapies for Non-Hodgkin Lymphoma — What Clinicians Want To Know

Join us on Friday, December 11^th from 7:00 PM to 9:00 PM central time (8:00 PM to 10:00 PM eastern time).

Module 1: Clinical Utility of CD19-Directed Monoclonal Antibodies for Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

• Design, eligibility criteria and emerging findings from the Phase III frontMIND trial assessing tafasitamab and lenalidomide with R-CHOP versus R-CHOP alone as first-line therapy for DLBCL
• Extended follow-up with tafasitamab/lenalidomide for relapsed/refractory (R/R) DLBCL; optimal sequencing for individual patients
• Key efficacy and safety findings from the Phase III inMIND trial evaluating the addition of tafasitamab to lenalidomide and rituximab (R²) in R/R FL or marginal zone lymphoma
• FDA approval of tafasitamab/R² for patients with R/R FL

Module 2: Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL

• Extended follow-up from the Phase II LOTIS-2 study supporting the use of loncastuximab tesirine for patients with R/R DLBCL
• Initial results from the Phase Ib LOTIS-7 study of loncastuximab tesirine in combination with glofitamab for R/R DLBCL
• Available data with loncastuximab tesirine for other subtypes of non-Hodgkin lymphoma (NHL)
• NCCN guideline inclusion of loncastuximab tesirine/rituximab as a third- or later-line treatment option for FL
• Spectrum, frequency, severity and optimal approach to management of toxicities associated with loncastuximab tesirine

Module 3: Potential Role of Cereblon E3 Ligase Modulators (CELMoDs) in the Management of NHL

• Mechanism of action of CELMoDs; similarities and differences between the CELMoD golcadomide and standard immunomodulatory drugs (IMiDs), such as lenalidomide
• Early efficacy and safety findings with golcadomide in combination with rituximab for heavily pretreated FL
• Preliminary outcomes documented with golcadomide-containing regimens for patients with newly diagnosed and R/R DLBCL
• Ongoing research efforts, such as the GOLSEEK-4, GOLSEEK-2 and GOLSEEK-1 trials, evaluating golcadomide-containing combination therapy for FL and DLBCL
• Potential clinical role of golcadomide in NHL management
• Spectrum, incidence and severity of side effects with golcadomide; similarities and differences from those associated with lenalidomide

Module 4: Current and Future Role of Bruton Tyrosine Kinase (BTK) Inhibition in the Management of NHL

• Key outcomes with the addition of acalabrutinib to bendamustine/rituximab and rituximab maintenance for patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for transplant
• Published findings with and ongoing studies of covalent BTK inhibitors as a component of up-front chemotherapy-free combination regimens for MCL
• Key data supporting the FDA approval of zanubrutinib/obinutuzumab for R/R FL
• Design, eligibility criteria and primary and secondary endpoints of the Phase III ESCALADE trial of acalabrutinib in combination with R-CHOP for patients age 65 or younger with untreated non-GCB DLBCL

Module 5: Role of Bcl-2 Inhibitors in the Management of MCL

• Available data with venetoclax as monotherapy or in combination with rituximab or a BTK inhibitor for patients with R/R MCL
• Available findings from the BGB-11417-201 trial evaluating sonrotoclax monotherapy for R/R MCL
• Other available datasets with sonrotoclax for MCL, including in combination with zanubrutinib
• Design, eligibility criteria and primary and secondary endpoints of the Phase III CELESTIAL-RRMCL study evaluating sonrotoclax with zanubrutinib compared to placebo with zanubrutinib for patients with R/R MCL

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-Hodgkin lymphoma.

Learning Objectives
At the conclusion of this activity, participants should be able to

• Understand published clinical research findings with CD19-targeted monoclonal antibodies as a component of combination treatment regimens for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), and apply this information in patient-education discussions. 
• Appraise the biological rationale for, available research findings with and current clinical role of CD19-targeted antibody-drug conjugates for patients with relapsed/refractory (R/R) DLBCL and FL.
• Evaluate available clinical trial findings with Bruton tyrosine kinase inhibitors for patients with mantle cell lymphoma (MCL), FL and DLBCL, and determine the utility of these agents in current and future clinical management.
• Assess the scientific basis for and available research findings with Bcl-2 inhibitors for patients with R/R MCL, and consider the current role of this novel therapeutic strategy.
• Review the mechanism of action and unique characteristics of cereblon E3 ligase modulators under development for FL and DLBCL, and appreciate available research findings with and ongoing studies evaluating the potential role of these novel agents.
• Recall new data with agents and strategies currently under investigation for various non-Hodgkin lymphoma subtypes, and discuss ongoing clinical trial opportunities with eligible patients.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY
Dr Caimi — Advisory Committees: AbbVie Inc, Autolus, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Novartis, Recordati; Consulting Agreements: Bristol Myers Squibb; Contracted Research: ADC Therapeutics, Genmab US Inc, Incyte Corporation, Iovance Biotherapeutics, Recordati; Data and Safety Monitoring Boards/Committees: ADC Therapeutics; Stock OPTIONS — Private Companies: Abcon Therapeutics. Dr Hoffmann — Advisory Committees: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Kite, A Gilead Company, Novartis; Consulting Agreements: AbbVie Inc; Data and Safety Monitoring Boards/ Committees: Novartis. Dr Kahl — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Lilly, Octapharma, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: Acrotech Biopharma, Bristol Myers Squibb, Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, Nurix Therapeutics Inc, PeproMene Bio Inc. Dr Strati — Advisory Committees and Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics, BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Kite, A Gilead Company, Lilly, Merck, Novartis, Regeneron Pharmaceuticals Inc, Sobi; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics, ALX Oncology, Kite, A Gilead Company, Sobi.

MODERATOR
Dr Smith — Advisory Committees: Genentech, a member of the Roche Group; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, Genentech, a member of the Roche Group; Contracted Research: Ipsen Biopharmaceuticals Inc. 

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb and Incyte Corporation.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom A/B — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.